Latest Strategy Changes News

Volt Group Limited reported a robust 26.8% revenue increase in Q1 FY25, driven by strong performances in its EcoQuip and Wescone divisions, alongside promising advances in its ATEN Waste Heat to Power technology.

Saferoads Holdings reports a modest quarterly profit driven by cost cuts and prepares to settle the sale of its Road Safety Rentals business, aiming to clear debt and refocus on product sales growth.

Cyprium Metals completed a A$15 million capital raise and formed a strategic alliance with Macmahon to accelerate the restart of its Nifty Copper Complex, while upgrading its Maroochydore copper-cobalt resource.

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

North Stawell Minerals Ltd reported a significant reduction in cash reserves for the quarter ending March 2025, highlighting a potential capital raising as exploration activities near completion.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

Eneco Refresh Limited reports solid 8% year-to-date revenue growth for Q3 FY2025, underpinned by gains in its water and plastics segments and improved cash flow.

Empire Energy Group reported significant cash outflows in Q1 2025 driven by exploration and infrastructure investments but bolstered its liquidity with new financing facilities, including a Midstream Infrastructure Facility for the Carpentaria Gas Plant.

Elixinol Wellness reported a 13.7% year-on-year revenue increase in Q1 FY25, despite a softer quarter compared to record Q4, with ecommerce momentum and strategic initiatives setting the stage for margin recovery and growth in H2.

The Star Entertainment Group reported a 9% revenue decline to $271 million in Q3 FY25 alongside a $21 million EBITDA loss, driven by seasonal factors and operational challenges. The company is advancing strategic investments and joint venture exits amid ongoing liquidity pressures and regulatory hurdles.

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.